Articles Referencing AVNR
Avanir to Expedite AVP-786 Development - Analyst Blog
6/6/2013, 7:27 pm from Zacks.com in Investing, Business, Stocks
Avanir Pharmaceuticals, Inc. ( AVNR ) recently held a
pre-IND (Investigational New Drug) meeting with the US Food and
Drug Administration (FDA) for its next-generation candidate,
AVP-786.... Read >>
Mid-Day Market Update: Markets Extend Losses, Mattress Firm Surges On Earnings Beat
6/5/2013, 12:36 pm from Benzinga in Investing, Commodities, Economy, International
Midway through trading Wednesday, the Dow traded down 0.76
percent to 15,062.00, while the NASDAQ fell 0.82 percent to
3,417.18. The S&P was also down, dropping 0.84 percent... Read >>
Mid-Morning Market Update: Markets Fall, Brown-Forman Posts Higher Profit
6/5/2013, 10:21 am from Benzinga in Investing, Commodities, Economy, International
Following the market opening Wednesday, the Dow traded down 0.23
percent to 15,142.59, while the NASDAQ fell 0.08 percent to
3,442.41. The S&P was also down, dropping 0.18 percent... Read >>
Pre-Market Most Active for Jun 5, 2013 : QQQ, BAC, GSK, GM, UBNT, FB, AEG, F, SAN, AVNR, MSFT, ASML
6/5/2013, 8:39 am from NASDAQ.com News in News Headlines, Pre-market Most Active
The NASDAQ 100
Pre-Market Indicator is down -9.25 to 2,964.44. The total
Pre-Market volume is currently 3,055,958 shares traded.
The following are the
most active stocks for the pre-market... Read >>
Weekly CEO Sells Highlight: Danaher Corporation, Orbitz Worldwide Inc. ...
5/20/2013, 11:04 am from GuruFocus in Investing
According to GuruFocus Insider Data , these are the largest
CEO sales during the past week: Danaher Corporation, Orbitz
Worldwide Inc., 3D Systems Corporation and AVANIR
Pharmaceuticals.
... Read >>
Wider-than-Expected Loss at Avanir - Analyst Blog
5/9/2013, 9:51 am from Zacks.com in Investing, Business, Stocks
Avanir Pharmaceuticals, Inc. ( AVNR ) reported second
quarter fiscal 2013 net loss per share of 12 cents, wider than the
Zacks Consensus Estimate of a loss of 9 cents, but narrower... Read >>
Positive CHMP Opinion for Avanir - Analyst Blog
5/1/2013, 10:48 am from Zacks.com in Investing, Business, Stocks
Avanir Pharmaceuticals, Inc. ( AVNR ) recently
received a positive opinion from the Committee for Medicinal
Products for Human Use (CHMP) for Nuedexta. Nuedexta is under review in the EU... Read >>
Pre-Market Most Active for Apr 26, 2013 : NOK, QQQ, ASML, BAC, MTU, RESI, JCP, BCS, FB, AVNR, ZNGA, SPNC
4/26/2013, 8:39 am from NASDAQ.com News in News Headlines, Pre-market Most Active
The NASDAQ 100
Pre-Market Indicator is down -6.63 to 2,842.03. The total
Pre-Market volume is currently 3,725,109 shares traded.
The following are the
most active stocks for the pre-market... Read >>
Anacor, Gates Foundation Collaborate - Analyst Blog
4/9/2013, 6:10 pm from Zacks.com in Investing, Business, Stocks
Anacor Pharmaceuticals, Inc. ( ANAC ) inked a deal
with the Bill & Melinda Gates Foundation for the discovery
of drug candidates for the treatment of two filarial worm... Read >>
Valeant: The Sole Suitor for Obagi - Analyst Blog
4/9/2013, 3:09 pm from Zacks.com in Investing, Business, Stocks
Valeant Pharmaceuticals ' ( VRX ) proposed
acquisition of Obagi Medical Products, Inc. ( OMPI ) received a
boost with Merz Pharma Group opting out of the race to purchase
Obagi. Merz's... Read >>
Valeant Inks Deal with Actavis - Analyst Blog
4/8/2013, 5:07 pm from Zacks.com in Investing, Business, Stocks
Valeant Pharmaceuticals ( VRX ) recently entered
into an agreement with Actavis Inc. ( ACT ). As per the
agreement, effective immediately, Actavis will exclusively market
and distribute... Read >>
Pipeline Progresses at Shire - Analyst Blog
4/5/2013, 5:10 pm from Zacks.com in Investing, Business, Stocks
Shire plc ( SHPG ) recently
enrolled the first patients for two phase II studies of its
candidate SRM003 (formerly Vascugel), which is being developed for
treating patients suffering from... Read >>
ArQule Regains ARQ 092 Rights - Analyst Blog
4/2/2013, 6:20 pm from Zacks.com in Investing, Business, Stocks
ArQule, Inc. ( ARQL ) recently
announced that the company has regained global rights for the
development and commercialization of compounds, which are covered
under its AKT collaboration... Read >>
Pernix Reports Loss in 4Q - Analyst Blog
3/21/2013, 2:33 pm from Zacks.com in Investing, Business, Stocks
Pernix Therapeutics Holdings, Inc ( PTX ) posted a loss of
2 cents per share in the fourth quarter of 2012 compared to
earnings of 15 cents per share in the year-ago quarter. ... Read >>
Data on Eli Lilly's Cialis - Analyst Blog
3/19/2013, 6:47 pm from Zacks.com in Investing, Business, Stocks
Eli Lilly and Company ( LLY ) recently
presented data on Cialis at the annual European Association of
Urology (EAU) Congress. Results from a 26-week, randomized,... Read >>